BR112022011177A2 - Domínios de repetição de anquirina projetados com resíduos de superfície alterados - Google Patents
Domínios de repetição de anquirina projetados com resíduos de superfície alteradosInfo
- Publication number
- BR112022011177A2 BR112022011177A2 BR112022011177A BR112022011177A BR112022011177A2 BR 112022011177 A2 BR112022011177 A2 BR 112022011177A2 BR 112022011177 A BR112022011177 A BR 112022011177A BR 112022011177 A BR112022011177 A BR 112022011177A BR 112022011177 A2 BR112022011177 A2 BR 112022011177A2
- Authority
- BR
- Brazil
- Prior art keywords
- proteins
- anchyrin
- surface residues
- altered surface
- repetition
- Prior art date
Links
- 102000004169 proteins and genes Human genes 0.000 abstract 5
- 108090000623 proteins and genes Proteins 0.000 abstract 5
- 102000039446 nucleic acids Human genes 0.000 abstract 3
- 108020004707 nucleic acids Proteins 0.000 abstract 3
- 150000007523 nucleic acids Chemical class 0.000 abstract 3
- 102000008102 Ankyrins Human genes 0.000 abstract 2
- 108010049777 Ankyrins Proteins 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B40/00—Libraries per se, e.g. arrays, mixtures
- C40B40/04—Libraries containing only organic compounds
- C40B40/10—Libraries containing peptides or polypeptides, or derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
- C07K16/082—Hepadnaviridae, e.g. hepatitis B virus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/74—Inducing cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2318/00—Antibody mimetics or scaffolds
- C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Cell Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Plant Pathology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Reproductive Health (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP19215433 | 2019-12-11 | ||
EP19215434 | 2019-12-11 | ||
EP19215436 | 2019-12-11 | ||
EP19215435 | 2019-12-11 | ||
EP20161059 | 2020-03-04 | ||
EP20181234 | 2020-06-19 | ||
PCT/EP2020/085855 WO2021116462A1 (fr) | 2019-12-11 | 2020-12-11 | Domaines de répétition d'ankyrine conçus avec des résidus de surface modifiés |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112022011177A2 true BR112022011177A2 (pt) | 2022-09-27 |
Family
ID=73790118
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112022011177A BR112022011177A2 (pt) | 2019-12-11 | 2020-12-11 | Domínios de repetição de anquirina projetados com resíduos de superfície alterados |
BR112022011456A BR112022011456A2 (pt) | 2019-12-11 | 2020-12-11 | Proteínas recombinantes de ligação a complexo de peptídeo-mhc e geração e uso das mesmas |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112022011456A BR112022011456A2 (pt) | 2019-12-11 | 2020-12-11 | Proteínas recombinantes de ligação a complexo de peptídeo-mhc e geração e uso das mesmas |
Country Status (11)
Country | Link |
---|---|
US (4) | US20220106707A1 (fr) |
EP (2) | EP4073092A2 (fr) |
JP (2) | JP2023506765A (fr) |
KR (2) | KR20220113492A (fr) |
CN (2) | CN114929730A (fr) |
AU (2) | AU2020399230A1 (fr) |
BR (2) | BR112022011177A2 (fr) |
CA (2) | CA3161326A1 (fr) |
IL (2) | IL293698A (fr) |
MX (2) | MX2022007120A (fr) |
WO (2) | WO2021116469A2 (fr) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2022007120A (es) | 2019-12-11 | 2022-09-09 | Molecular Partners Ag | Proteínas de unión al complejo péptido-mhc recombinantes y su generación y uso. |
JP2023525518A (ja) | 2020-05-06 | 2023-06-16 | モレキュラー パートナーズ アクチェンゲゼルシャフト | 新規アンキリンリピート結合タンパク質とその用途 |
EP3957649A1 (fr) * | 2020-08-18 | 2022-02-23 | Athebio AG | Modules de coiffage de domaines de répétition d'ankyrine à n-terminaux améliorés |
US11981710B2 (en) | 2020-08-18 | 2024-05-14 | Athebio Ag | N-terminal capping modules of ankyrin repeat domains |
EP4304731A1 (fr) | 2021-03-09 | 2024-01-17 | Molecular Partners AG | Nouveaux agents de mise en contact de lymphocytes t multi-spécifiques à base de darpin |
EP4137508A1 (fr) * | 2021-08-17 | 2023-02-22 | Athebio AG | Variantes de domaines de répétition d'ankyrine |
WO2023021050A1 (fr) * | 2021-08-17 | 2023-02-23 | Athebio Ag | Variants de domaines de répétition d'ankyrine |
AU2022413461A1 (en) | 2021-12-14 | 2024-06-06 | Molecular Partners Ag | Designed repeat domains with dual binding specificity and their use |
CA3240046A1 (fr) * | 2021-12-14 | 2023-06-22 | Cdr-Life Ag | Activateur double de lymphocytes t ciblant le cmh |
WO2024028278A1 (fr) | 2022-08-01 | 2024-02-08 | Molecular Partners Ag | Domaines de répétition conçus à charges modifiées et leur utilisation |
Family Cites Families (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5804381A (en) | 1996-10-03 | 1998-09-08 | Cornell Research Foundation | Isolated nucleic acid molecule encoding an esophageal cancer associated antigen, the antigen itself, and uses thereof |
CA2421447C (fr) | 2000-09-08 | 2012-05-08 | Universitat Zurich | Groupes de proteines a domaines de repetition comprenant des modules de repetition |
WO2003070752A2 (fr) | 2002-02-20 | 2003-08-28 | Dyax Corporation | Ligands de liaison au complexe mhc-peptide |
CN101056646A (zh) | 2004-11-12 | 2007-10-17 | 拜耳先灵医药股份有限公司 | 重组新城疫病毒 |
DK1902131T3 (da) | 2005-07-08 | 2010-03-01 | Univ Zuerich | Fag-display under anvendelse af cotranslational translokation af fusionspolypeptider |
EP2565204B1 (fr) | 2007-07-27 | 2015-10-07 | immatics biotechnologies GmbH | Nouveaux épitopes immunogènes pour l'immunothérapie |
US9365629B2 (en) | 2007-09-24 | 2016-06-14 | University Of Zurich | Designed armadillo repeat proteins |
NZ592591A (en) | 2008-11-03 | 2012-04-27 | Molecular Partners Ag | Binding proteins comprising ankyrin repeast domains that inhibit the vegf-a receptor interaction |
AR081361A1 (es) | 2010-04-30 | 2012-08-29 | Molecular Partners Ag | Proteinas de union modificadas que inhiben la interaccion de receptor del factor de crecimiento endotelial vascular de glicoproteina a vegf-a |
JP6173216B2 (ja) | 2010-11-26 | 2017-08-02 | モレキュラー・パートナーズ・アーゲーMolecular Partners Ag | 設計アンキリンリピートタンパク質のための改善されたキャッピングモジュール |
KR20140039203A (ko) * | 2011-04-29 | 2014-04-01 | 얀센 바이오테크 인코포레이티드 | Il4/il13 결합 반복 단백질 및 용도 |
CN104508129A (zh) | 2012-06-28 | 2015-04-08 | 分子伴侣公司 | 设计的与血小板衍生生长因子结合的锚蛋白重复序列蛋白 |
WO2014060365A1 (fr) | 2012-10-15 | 2014-04-24 | Universität Zürich Prorektorat Mnw | Ligands her2 bispécifiques pour la thérapie du cancer |
EP2738180A1 (fr) * | 2012-11-30 | 2014-06-04 | Molecular Partners AG | Protéines de liaison comportant au moins deux domaines de liaison ciblant HER2 |
JP6486908B2 (ja) | 2013-05-31 | 2019-03-20 | モレキュラー パートナーズ アクチェンゲゼルシャフト | 肝細胞増殖因子に結合する設計アンキリン反復タンパク質 |
BR112016021004A2 (pt) | 2014-03-14 | 2018-01-23 | Immunocore Limited | biblioteca de partículas; receptor de células t (tcr) isolado não natural; uso de uma biblioteca; método de obtenção de um receptor de células t que se liga especificamente a um antígeno de peptídeo; ácido nucleico; método de construção de uma biblioteca de partículas; método de obtenção de um receptor de células t que se liga especificamente a um antígeno de peptídeo; e partícula |
US20170226158A1 (en) * | 2014-08-11 | 2017-08-10 | Medimmune Limited | Intracellular antigen binding |
AU2016235251B2 (en) | 2015-03-23 | 2022-03-17 | The Johns Hopkins University | HLA-restricted epitopes encoded by somatically mutated genes |
SG11201707606RA (en) | 2015-04-02 | 2017-10-30 | Molecular Partners Ag | Designed ankyrin repeat domains with binding specificity for serum albumin |
CA3025894A1 (fr) | 2016-06-02 | 2017-12-07 | Immunocore Limited | Schema de traitement pour proteine de fusion scfv tcr-anti-cd3 gp100 specifique |
WO2018054971A1 (fr) | 2016-09-22 | 2018-03-29 | Molecular Partners Ag | Protéines de liaison recombinantes et leur utilisation |
EP3710042A4 (fr) * | 2017-11-16 | 2021-11-24 | The Regents of The University of California | Polypeptides chimériques contenant un domaine de clivage par capteur de force et leurs méthodes d'utilisation |
JP2022535106A (ja) | 2019-06-04 | 2022-08-04 | モレキュラー パートナーズ アクチェンゲゼルシャフト | 改善された安定性を有する設計されたアンキリン反復ドメイン |
KR20220016942A (ko) | 2019-06-04 | 2022-02-10 | 몰리큘라 파트너스 아게 | 재조합 fap 결합 단백질 및 이의 용도 |
JP2022535564A (ja) | 2019-06-04 | 2022-08-09 | モレキュラー パートナーズ アクチェンゲゼルシャフト | 多選択性タンパク質 |
JP2022535107A (ja) | 2019-06-04 | 2022-08-04 | モレキュラー パートナーズ アクチェンゲゼルシャフト | 組換え4-1bb結合タンパク質及びそれらの使用 |
EP4073093A2 (fr) | 2019-12-11 | 2022-10-19 | Molecular Partners AG | Protéines de liaison de complexe peptide-mhc de recombinaison, leur production et leur utilisation |
MX2022007120A (es) | 2019-12-11 | 2022-09-09 | Molecular Partners Ag | Proteínas de unión al complejo péptido-mhc recombinantes y su generación y uso. |
JP2023525518A (ja) * | 2020-05-06 | 2023-06-16 | モレキュラー パートナーズ アクチェンゲゼルシャフト | 新規アンキリンリピート結合タンパク質とその用途 |
KR20230022176A (ko) | 2020-05-14 | 2023-02-14 | 몰리큘라 파트너스 아게 | 다중특이적 단백질 |
EP4149960A1 (fr) | 2020-05-14 | 2023-03-22 | Molecular Partners AG | Protéines de liaison à cd40 recombinantes et leur utilisation |
-
2020
- 2020-12-11 MX MX2022007120A patent/MX2022007120A/es unknown
- 2020-12-11 KR KR1020227023764A patent/KR20220113492A/ko active Search and Examination
- 2020-12-11 CN CN202080093012.7A patent/CN114929730A/zh active Pending
- 2020-12-11 EP EP20821221.7A patent/EP4073092A2/fr active Pending
- 2020-12-11 BR BR112022011177A patent/BR112022011177A2/pt not_active Application Discontinuation
- 2020-12-11 CA CA3161326A patent/CA3161326A1/fr active Pending
- 2020-12-11 AU AU2020399230A patent/AU2020399230A1/en active Pending
- 2020-12-11 IL IL293698A patent/IL293698A/en unknown
- 2020-12-11 JP JP2022535453A patent/JP2023506765A/ja active Pending
- 2020-12-11 IL IL293704A patent/IL293704A/en unknown
- 2020-12-11 JP JP2022535443A patent/JP2023506757A/ja active Pending
- 2020-12-11 CN CN202080093076.7A patent/CN115003689A/zh active Pending
- 2020-12-11 BR BR112022011456A patent/BR112022011456A2/pt not_active Application Discontinuation
- 2020-12-11 MX MX2022007122A patent/MX2022007122A/es unknown
- 2020-12-11 EP EP20821220.9A patent/EP4073091A1/fr active Pending
- 2020-12-11 CA CA3161321A patent/CA3161321A1/fr active Pending
- 2020-12-11 AU AU2020402581A patent/AU2020402581A1/en active Pending
- 2020-12-11 WO PCT/EP2020/085863 patent/WO2021116469A2/fr unknown
- 2020-12-11 KR KR1020227023763A patent/KR20220113491A/ko unknown
- 2020-12-11 WO PCT/EP2020/085855 patent/WO2021116462A1/fr unknown
-
2021
- 2021-08-02 US US17/392,204 patent/US20220106707A1/en not_active Abandoned
- 2021-08-12 US US17/400,471 patent/US11578427B2/en active Active
-
2023
- 2023-01-12 US US18/153,576 patent/US20230340698A1/en active Pending
- 2023-02-24 US US18/174,086 patent/US20230243070A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US20220106707A1 (en) | 2022-04-07 |
JP2023506765A (ja) | 2023-02-20 |
US20230340698A1 (en) | 2023-10-26 |
WO2021116469A2 (fr) | 2021-06-17 |
IL293704A (en) | 2022-08-01 |
US20230243070A1 (en) | 2023-08-03 |
EP4073092A2 (fr) | 2022-10-19 |
US20220064234A1 (en) | 2022-03-03 |
AU2020402581A9 (en) | 2022-07-14 |
IL293698A (en) | 2022-08-01 |
CN115003689A (zh) | 2022-09-02 |
CN114929730A (zh) | 2022-08-19 |
US11578427B2 (en) | 2023-02-14 |
KR20220113492A (ko) | 2022-08-12 |
CA3161321A1 (fr) | 2021-06-17 |
AU2020399230A1 (en) | 2022-06-23 |
CA3161326A1 (fr) | 2021-06-17 |
WO2021116462A1 (fr) | 2021-06-17 |
JP2023506757A (ja) | 2023-02-20 |
WO2021116469A3 (fr) | 2021-12-02 |
BR112022011456A2 (pt) | 2022-08-23 |
AU2020402581A1 (en) | 2022-06-23 |
KR20220113491A (ko) | 2022-08-12 |
MX2022007120A (es) | 2022-09-09 |
MX2022007122A (es) | 2022-09-09 |
EP4073091A1 (fr) | 2022-10-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112022011177A2 (pt) | Domínios de repetição de anquirina projetados com resíduos de superfície alterados | |
BR112019005587A2 (pt) | proteínas de ligação recombinantes e sua utilização | |
BR112012027765A2 (pt) | métodos, composições e kits para tratamento de distúrbios de mineralização da matriz. | |
BR112017016765A2 (pt) | composição para tratamento de tecido compreendendo ésteres de poliol insaturados metatetizados | |
BR112018000604A2 (pt) | moléculas de anticorpo que ligam cd45 | |
CO2017009433A2 (es) | Proteínas específicas para pioverdina y pioquelina | |
CL2023001338A1 (es) | Ácidos nucleicos recombinantes que codifican una o más proteínas cosméticas para usos estéticos. | |
PH12017501792A1 (en) | Recombinant binding proteins and their use | |
BR112019010265A2 (pt) | anticorpos anti_cd137 inovadores e usos dos mesmos | |
BR112022022456A2 (pt) | Proteínas de ligação de repetição de anquirina e seus usos | |
UY36578A (es) | Proteínas de unión a tslp | |
CL2019000732A1 (es) | Tratamiento avv de la enfermedad de huntington. | |
BR112018014288A2 (pt) | métodos e composições para o tratamento de doença neurológica | |
BR112019017403A2 (pt) | composições e métodos para o tratamento de câncer | |
BR112017023692A2 (pt) | moléculas imunoterapêuticas glican-dependentes | |
EA201890320A1 (ru) | Молекулы антител, которые связывают cd79 | |
MX2023001877A (es) | Meganucleasas dise?adas especificas para secuencias de reconocimiento en el gen pcsk9. | |
BR112017015833A2 (pt) | compostos anti-senescência e usos dos mesmos | |
BR112022023049A2 (pt) | Proteínas multiespecíficas | |
BR112019007210A2 (pt) | métodos e composições para o tratamento da doença de fabry | |
BR112018014590A2 (pt) | formulações/composições compreendendo um inibidor de btk | |
BR112022005687A2 (pt) | Vacinas contra o hbv e métodos para tratar o hbv | |
BR112018014540A2 (pt) | formulações/composições compreendendo inibidor de btk | |
EA202091769A1 (ru) | Вакцины против вируса гриппа и пути их применения | |
BR112018007121A2 (pt) | anticorpo ou antígeno de ligação ao fragmento do mesmo, anticorpo humanizado ou um fragmento de ligação ao antígeno do mesmo, molécula de ácido nucléico isolada, vetor, célula hospedeira, método para preparar o anticorpo ou um antígeno de ligação ao fragmento do mesmo, composição farmacêutica, uso do anticorpo ou um antígeno de ligação ao fragmento do mesmo e método para prevenir ou tratar infecção hbv ou uma doença associada com a infecção hbv |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |